NEWS
Around stable-isotope drugs, MR metabolic imaging and the drug-device ecosystem, recording the company's key milestones from research breakthroughs to clinical translation.
Latest Updates
The company has obtained the NMPA Drug Clinical Trial Approval Notice, as the world’s first deuterated glucose molecular tracer advances into the clinical research stage.
The company has submitted a pre-IND application to the NMPA, advancing clinical registration of the world's first deuterated glucose molecular tracer.
Centered on 3T, 5T and 7T multi-nuclear MR systems, advancing the deployment of deuterium metabolic imaging across research and clinical scenarios.
Partnering with equipment vendors to advance metabolic-MR equipment upgrades, tracer integration and clinical translation.
The company's deuterated glucose product matches international benchmarks in performance and has obtained a granted Chinese invention patent.
Media Kit
Company positioning, product pipeline, clinical value and partner ecosystem — the four most important categories for media coverage and industry communication.
